Skeletal Fluorosis — Comprehensive Research Report

1. Disease Information

Overview. Skeletal fluorosis (SF) is a chronic metabolic bone and joint disease caused by long-term excessive systemic fluoride exposure, most often from fluoride-contaminated groundwater but also from occupational inhalation, brick tea, coal-smoke indoor air pollution, or fluoride-containing consumer products (toothpaste, inhalant abuse of fluorinated computer-cleaner propellants, methoxyflurane analgesia). Fluoride has a very high affinity for calcium and is progressively deposited in the mineral phase of bone, producing a syndrome of active osteogenesis and accelerated, disorganized bone turnover that manifests as diffuse osteosclerosis, osteopenia in some compartments, exostoses, ligament/tendon ossification, and — in advanced disease — mechanical compression of the spinal cord and nerve roots (PMID:3295994; MONDO:0400003 definition).

Key identifiers: - MONDO: MONDO:0400003 — "Skeletal fluorosis," defined as "A condition that results from excessive fluoride ingestion leading to fluoride accumulation in the bone progressively over many years. The early symptoms...include stiffness and pain in the joints" (synonym: "Fluorosis of the skeleton") — cross-referenced to ICD10CM:M85.1 and WHO ICD-11 entity 1269698463 (https://www.ebi.ac.uk/ols4/ontologies/mondo). - ICD-10-CM: M85.1– series ("Disorders of bone density and structure, fluorosis of bone"), with laterality/site-specific subcodes (e.g., M85.10 unspecified site, M85.15 thigh, M85.159 unspecified thigh, M85.162 left lower leg) (icd10data.com; aapc.com). - ICD-11: Entity 1269698463 (WHO ICD API). - A separate, related but distinct entity is dental fluorosis (MONDO:0006722), an enamel-formation disorder from fluoride exposure during odontogenesis (age <8 years) — do not conflate with skeletal fluorosis, which reflects lifetime cumulative bone fluoride burden. - MeSH: Fluorosis, Dental (D005506) is indexed separately from bone-fluoride toxicity literature, which is typically indexed under "Fluorides/adverse effects" and "Fluorosis, Skeletal" is not a standalone current MeSH heading in all databases — most PubMed indexing uses "Fluorides/poisoning" + "Bone Diseases." - Synonyms/alternative names: endemic skeletal fluorosis; osteofluorosis; crippling fluorosis; fluoride osteosclerosis; brick-tea-type fluorosis (a specific etiologic subtype); industrial/occupational fluorosis. - Evidence provenance: The overwhelming majority of the literature is aggregated disease-level epidemiological, radiographic, and mechanistic data from endemic-region surveys (India, China) and animal studies, supplemented by individual case reports for atypical, non-endemic exposures (inhalant abuse, occupational, methoxyflurane, excessive toothpaste ingestion) rather than large EHR-derived cohorts.

2. Etiology

2a. Disease causal factors

Skeletal fluorosis is fundamentally an environmental/toxicological disease, not a Mendelian genetic disorder — the causal factor is chronic excess systemic fluoride intake exceeding the body's excretory (renal) capacity, leading to net fluoride retention in bone mineral. There is no single causal gene; genetic factors instead modulate individual susceptibility to a given fluoride dose (see below).

2b. Risk factors

Environmental/exposure risk factors (the dominant category): - Groundwater fluoride contamination — geogenic fluoride from fluoride-bearing minerals (fluorite, apatite, mica) leaching into groundwater in arid/semi-arid regions with high evapotranspiration and alkaline, calcium-poor aquifers (Rift Valley belt — Ethiopia, Kenya, Tanzania, Uganda, Eritrea, Djibouti — plus India, China, Sri Lanka, Türkiye). WHO's drinking-water guideline value is 1.5 mg/L; concentrations above this are associated with dental fluorosis, and total fluoride intake >6 mg/day is associated with crippling skeletal fluorosis (WHO guidance; search results above). - Brick tea / instant tea consumption — tea plants bioaccumulate fluoride from soil/air (up to 98% of ambient fluoride can be sequestered in leaves), and brick tea (made from older leaves/stalks) is markedly higher in fluoride than leaf tea; "brick-tea-type fluorosis" is a distinct, well-described etiologic subtype endemic to Tibetan, Mongolian, and other pastoralist populations in China (PMID:39824337; PMC4728115). - Indoor coal-burning — combustion of high-fluoride coal for cooking/heating in unventilated homes in southwestern China causes fluoride-laden smoke exposure and food contamination (crops dried over open coal fires), producing pediatric skeletal fluorosis (PMC2778178). - Occupational/industrial exposure — aluminum smelting (cryolite/fluoride aerosols), phosphate fertilizer manufacturing, and other fluoride-emitting industries (PMC2993488, Czechoslovakia occupational cohort). - Iatrogenic/consumer sources — chronic methoxyflurane analgesic use (metabolized to inorganic fluoride), excessive fluoridated toothpaste ingestion, and inhalant abuse of fluorinated hydrocarbon computer-cleaner propellants (difluoroethane) are documented non-endemic causes (PMC7336600, JBMR Plus 2024 ziae032). - Age, sex — Radiographic changes are most pronounced in middle age (40–60 years); several Indian endemic-village surveys report higher prevalence in males (e.g., 56.9% male vs 43.1% female skeletal fluorosis in Vidharbha region, Maharashtra), likely reflecting greater outdoor water/occupational intake and possibly body-size/metabolic differences (PMC2940190). - Nutritional status — low dietary calcium and protein-calorie malnutrition increase susceptibility to fluoride's skeletal effects by increasing fractional intestinal fluoride absorption and reducing competitive calcium binding.

Genetic risk/modifier factors (susceptibility, not causation): - ESR1 (estrogen receptor α) polymorphism rs9340799: the G allele is reported protective against brick-tea-type skeletal fluorosis in a multi-ethnic Chinese cohort (Tibetan, Kazakh, Mongolian, Russian) (PMID:39824337). - COL1A1 polymorphism rs1800012: the T allele confers significantly higher risk of skeletal fluorosis, an effect most pronounced in Russian men in the same cohort (PMID:39824337). - Animal (mouse strain) data corroborate a genetic component: A/J mice are a "susceptible" strain and 129P3/J a "resistant" strain for fluoride-induced skeletal/dental effects, with strain-dependent bone fluoride incorporation and proteomic responses even at low fluoride doses (PMID:16920415; PMC4263599).

2c. Protective factors

• Adequate dietary calcium and vitamin D intake reduces net skeletal fluoride uptake and, in mouse models, alleviates dental and skeletal fluorosis while preserving elemental (Ca/P) homeostasis (PMID:33057951).
• The ESR1 rs9340799 G allele (above) is a genetic protective variant in the tea-fluorosis context.
• Public-health defluoridation of drinking water (see Prevention) is the principal population-level protective intervention.

2d. Gene–environment interactions

The COL1A1/ESR1 findings above are explicitly framed as gene–environment interactions: susceptibility differs by ethnicity and appears to be modified by tea fluoride intake, sex, and age — i.e., the same genotype confers different risk depending on exposure route/dose (PMID:39824337). Mouse-strain data similarly show that a fixed environmental fluoride dose produces markedly different bone fluoride incorporation and proteomic/skeletal responses depending on genetic background (PMID:16920415).

3. Phenotypes

Symptoms / clinical signs (with suggested HPO terms)

Laboratory abnormalities

• Elevated urinary fluoride — the primary chemical biomarker; recent exposure reflected within 1–3 weeks, with reported values of ~15–20 ppm in affected humans/animals vs. 2–6 ppm normal (comparative veterinary literature; PMC search results).
• Bone-ash fluoride concentration (from biopsy) — considered the gold-standard definitive diagnostic measure, but invasive and rarely performed clinically.
• Elevated serum PTH with chronic fluoride exposure (secondary/tertiary hyperparathyroidism-like state; PMC8584317).
• Alkaline phosphatase elevation reflecting high bone turnover.
• Serum fluoride itself is not reliably diagnostic ("serum parameters rarely help in the diagnosis" — search synthesis above), because it reflects only very recent intake, not cumulative skeletal burden.

Phenotype characteristics

• Onset: Adult-onset in most endemic (waterborne) cases after years to decades of cumulative exposure; pediatric-onset described in indoor coal-burning fluorosis in southwestern China (PMC2778178) and rare acute/subacute cases from inhalant abuse or methoxyflurane over months.
• Severity/progression: Progressive with cumulative dose and duration; graded by China's national standard WS/T192-2021 into Grade I (symptoms, no radiographic/physical signs), Grade II (typical clinical/radiographic manifestations, retains some work capacity), and Grade III (loss of work capacity/crippling disease) (search synthesis).
• Frequency of neurologic involvement: Neurologic complications (myelopathy ± radiculopathy) occur in an estimated 5–10% of skeletal fluorosis cases, typically after >4 ppm fluoride exposure for >10 years; among those with neurologic disease, myelopathy alone accounts for ~72% and myelopathy+radiculopathy ~28% (PMID:2172892, Neurology India review).

Quality of life impact

Skeletal fluorosis causes "severe crippling disease which impairs the health-related quality of life in affected subjects," with case-report literature describing prolonged, sometimes decade-long, disability (search synthesis of ScienceDirect case-series review and JBMR "Recovery from Skeletal Fluorosis" case, PMID:17014382). No disease-specific EQ-5D/SF-36 dataset was identified in this search; QoL impact is documented narratively rather than via validated instrument scores in the literature surveyed.

4. Genetic/Molecular Information

Skeletal fluorosis is not a monogenic Mendelian disease — there is no single causal gene, OMIM entry, or pathogenic-variant classification analogous to a genetic disorder. Genetic information relevant to this entry is restricted to susceptibility/modifier loci:

• ESR1 (estrogen receptor alpha; HGNC:3467) — variant rs9340799 (intron 1, "PvuII" site); G allele protective in brick-tea-type fluorosis (PMID:39824337). Functional consequence: modifies estrogen-responsive transcriptional regulation of osteoblast activity, consistent with estrogen's known role in bone remodeling.
• COL1A1 (collagen type I alpha 1 chain; HGNC:2197) — variant rs1800012 (Sp1 binding site polymorphism, well known in osteoporosis genetics); T allele associated with increased skeletal fluorosis risk, especially in Russian men in the Chinese multi-ethnic cohort (PMID:39824337). This is the same polymorphism long studied for osteoporotic fracture risk, consistent with a shared collagen-matrix-quality mechanism.
• COL1A2 (HGNC:2198) — polymorphism rs412777 studied in relation to dental (not skeletal) fluorosis in a Tunisian population (PMC10958825) — noted here as an adjacent finding but not directly established for the skeletal phenotype.
• No ClinVar/ClinGen pathogenic-variant curation applies (this is a toxic/environmental exposure disease, not a variant-driven disorder), so ACMG/AMP classification, allele-frequency-database (gnomAD), and somatic/germline-origin fields are not applicable.
• Epigenetic changes (directly mechanistic, see Section 6) are the most substantive "genetic/molecular" content specific to this disease: DNA hypermethylation of p16, BMP1, METAP2, MMP11, BACH1; hypomethylation of ERα; and dysregulation of microRNAs miR-486-3p, miR-4755-5p, Let-7c-5p, miR-29a, miR-27 (PMC8584317, detailed in Section 6).
• Chromosomal abnormalities: none reported; not a chromosomal disorder.

5. Environmental Information

• Primary environmental factor: chronic excess fluoride ingestion, principally via drinking water with geogenic fluoride contamination exceeding WHO's 1.5 mg/L guideline (search synthesis; PMID citations above). ECTO/ENVO-relevant exposure route: ingestion of fluoride-contaminated water.
• Dietary/lifestyle factor: habitual consumption of brick tea or instant tea concentrate (documented reversal after tea cessation/reduction — ScienceDirect S237606052030465X, "long-term follow-up after reduction and discontinuation of tea").
• Occupational exposure: aluminum electrolytic production, phosphate fertilizer manufacture, and other fluoride/hydrogen-fluoride-emitting industrial processes (PMC2993488).
• Indoor air pollution: fluoride-laden smoke from unventilated indoor coal-burning stoves, compounded by crop-drying practices over open coal fires that further contaminate food with fluoride (PMC2778178, southwestern China pediatric cohort).
• Consumer product/iatrogenic exposure: difluoroethane-propelled computer-duster inhalant abuse (PMC7336600); chronic methoxyflurane analgesic use (JBMR Plus ziae032); excessive fluoridated toothpaste ingestion.
• Infectious agents: not applicable — skeletal fluorosis has no infectious etiology.
• Geographic/climatic modifiers: arid and semi-arid climates with high evapotranspiration concentrate fluoride in groundwater; the East African Rift Valley, the Indian subcontinent, and northern/southwestern China are the classic endemic belts (search synthesis; PMC13275634 "Global groundwater contamination by geogenic fluoride").

6. Mechanism / Pathophysiology

Ordered causal chain (initiating exposure → clinical manifestation)

1. Chronic excess fluoride intake (contaminated water, brick tea, coal smoke, industrial exposure, or iatrogenic source) leads to sustained elevation of systemic fluoride ion (F⁻) levels beyond renal excretory capacity.
2. Elevated systemic F⁻ results in progressive fluoride deposition into the hydroxyapatite mineral lattice of bone, substituting for hydroxyl groups to form fluorapatite — fluoride's high calcium affinity drives this preferential skeletal sequestration (PMID:3295994).
3. Bone-incorporated fluoride, together with circulating fluoride acting on bone-lining cells, triggers a shift in local signaling in osteoblasts and osteocytes: fluoride activates Wnt/β-catenin signaling (by suppressing the inhibitors SOST and Dkk-1, allowing β-catenin nuclear accumulation) and Hedgehog signaling (via increased Indian Hedgehog → Smoothened → Gli2), both converging on upregulation of Runx2, the master osteoblast transcription factor, while fluoride simultaneously suppresses Notch signaling (decreased Notch-3/Jagged-1), removing an inhibitory brake on osteoblast proliferation (PMC8584317).
4. This signaling shift leads to excessive, disorganized osteoblast proliferation and matrix (collagen I, alkaline phosphatase, osteonectin) synthesis, mediated in part by fluoride-induced Akt/GSK-3β phosphorylation that stabilizes β-catenin (PMID:24300170).
5. In parallel, elevated serum PTH (a systemic response to chronic fluoride/calcium perturbation) results in further downregulation of SOST and upregulation of RANKL, coupling excess osteoblastic activity to increased osteoclastogenesis via the osteocyte-driven RANK–JNK–NFATc1 pathway (PMID:32156525) — this is the mechanistic basis for the disease's hallmark of accelerated bone turnover rather than pure bone formation.
6. At high, sustained fluoride concentrations, cellular defenses are overwhelmed: fluoride induces oxidative stress (ROS accumulation overwhelming the Nrf2-ARE antioxidant response), endoplasmic reticulum stress (PERK-mediated unfolded protein response, upregulated BiP/GRP78, ATF4), and mitochondria-mediated apoptosis with increased mitophagy in osteocytes (Springer 2023 study), leading to disordered osteocyte viability and further dysregulated bone remodeling signals (PMC8584317; Springer/Biological Trace Element Research).
7. Concurrently, fluoride inhibits vitamin D hydroxylation, decreasing active vitamin D bioavailability and impairing intestinal calcium/phosphorus absorption, which — together with fluoride's direct calcium sequestration in bone — disturbs systemic phosphorus/calcium balance (search synthesis).
8. Epigenetic reprogramming accompanies and reinforces these changes: hypermethylation of the cell-cycle checkpoint gene p16 (reducing its expression and removing G1/S checkpoint control) and of BMP1, METAP2, MMP11, BACH1, alongside hypomethylation of ERα, and dysregulation of microRNAs (miR-486-3p↓, miR-4755-5p↓, Let-7c-5p↓ → increased Cyclin D1 → osteoblast proliferation; miR-29a↑ → decreased Dkk-1 → enhanced Wnt signaling; miR-27 positively correlated with β-catenin), collectively sustaining the pro-osteogenic, hyperproliferative osteoblast phenotype over years of chronic exposure (PMC8584317).
9. The net structural consequence — cumulative over years to decades — is diffuse osteosclerosis, cortical thickening, exostoses, and ossification of ligaments/tendons (interosseous membranes, posterior longitudinal ligament, ligamentum flavum, entheses), radiographically the disease's defining feature (search synthesis; AJR PMID reference; Radiopaedia).
10. In the spine specifically, this ligamentous/vertebral ossification and osteophytosis narrows the spinal canal and intervertebral foramina, which leads to (branch point) either (a) mechanical/compressive myelopathy and radiculopathy via direct cord/root compression, occurring in ~5–10% of cases after >10 years of high (>4 ppm) exposure (PMID:2172892), progressing in advanced cases to vascular/ischemic secondary injury of the cord, manifesting clinically as spastic quadriparesis, spasms, and urinary incontinence; or (b) purely peripheral musculoskeletal disease — joint stiffness, restricted mobility, and chronic pain — without neurologic compromise, in the majority of affected individuals.
11. In cartilage, a separate downstream branch occurs in chondrocytes: fluoride-induced oxidative stress suppresses the pentose phosphate pathway (decreased NADPH/GSH) and downregulates PI3K/Akt/mTOR while activating autophagy (increased Beclin-1, LC3) and upregulating MMP-13/RANKL, resulting in chondrocyte apoptosis and matrix degradation, contributing to joint/cartilage pathology alongside the primary bone-driven mechanism (PMID:39959228, PMID:41601087).

Detail by category

• Molecular pathways (KEGG/Reactome-relevant): Wnt signaling pathway (activated), Notch signaling pathway (suppressed), Hedgehog signaling pathway (activated in osteoblasts; pro-apoptotic in chondrocytes via Bax↑/Bcl-2↓), PI3K-Akt signaling pathway (activated in osteoblasts, suppressed in chondrocytes), RANK/RANKL/OPG axis (shifted toward increased RANKL), IL-17A pathway, MAPK/NQO1/HO1 pathway, PTH/PTHrP signaling, insulin/IGF-1 signaling (PMC8584317; PubMed synthesis).
• Cellular processes (GO-relevant): osteoblast proliferation and differentiation (GO:0002062 chondrocyte differentiation; GO:0030282 bone mineralization), osteoclast differentiation (GO:0030316), apoptosis (GO:0006915), autophagy (GO:0006914), mitophagy, oxidative stress response (GO:0006979), unfolded protein response/ER stress (GO:0030968), chronic inflammation.
• Protein dysfunction: no single misfolded protein; instead, fluoride acts as an enzymatic/ionic perturbant — inhibiting osteoblastic acid phosphatase (proposed mitogenic mechanism, ScienceDirect 0026049589902321), altering collagen (COL1A1) matrix quality, and disrupting vitamin-D-hydroxylase enzymatic activity.
• Metabolic changes: disturbed calcium-phosphorus homeostasis; impaired vitamin D activation; altered bone mineral (fluorapatite substitution for hydroxyapatite) reducing mechanical strength despite increased radiographic density.
• Immune system involvement: chronic low-grade inflammation and IL-17A pathway activation are implicated but are secondary/contributory rather than primary autoimmune mechanisms (PMC8584317).
• Tissue damage mechanisms: oxidative stress (ROS/MDA elevation), apoptosis, mitochondrial dysfunction/mitophagy in osteocytes, and secondary vascular/ischemic injury to compressed neural tissue.
• Biochemical abnormalities: elevated PTH, altered alkaline/acid phosphatase activity, disrupted calcium/phosphate/vitamin D axis, calcineurin (CaN) activation promoting osteoclastogenesis.
• Epigenetic changes: detailed above (DNA methylation of p16, BMP1, METAP2, MMP11, BACH1, ERα; miRNA dysregulation).
• Molecular profiling: proteomic studies (iTRAQ, Wistar rat serum) have identified candidate serum protein biomarkers of fluorosis (PMC5085677); murine bone proteomics show 36 differentially abundant proteins even at low-dose fluoride exposure in susceptible (A/J) mice (PMC4263599). No large-scale human transcriptomic/single-cell atlas specific to skeletal fluorosis was identified in this search.

Suggested GO terms

• GO:0030282 (bone mineralization)
• GO:0001649 (osteoblast differentiation)
• GO:0030316 (osteoclast differentiation)
• GO:0060070 (canonical Wnt signaling pathway)
• GO:0007219 (Notch signaling pathway)
• GO:0007224 (smoothened signaling pathway, Hedgehog)
• GO:0043491 (protein kinase B signaling, PI3K/Akt)
• GO:0006915 (apoptotic process)
• GO:0006979 (response to oxidative stress)
• GO:0034976 (response to endoplasmic reticulum stress)
• GO:0006914 (autophagy)

Suggested CL terms

• CL:0000062 (osteoblast)
• CL:0000137 (osteocyte)
• CL:0000092 (osteoclast)
• CL:0000138 (chondrocyte)

7. Anatomical Structures Affected

• Organ level: primary — the skeletal system (axial > appendicular skeleton, especially spine, pelvis, forearm), teeth (concurrent dental fluorosis when exposure begins before age 8). Secondary/complication involvement — spinal cord and peripheral nerve roots (compressive myelopathy/radiculopathy in advanced disease), skeletal muscle (biopsy studies document muscle changes in endemic SF, PMID:10878791), and, per some reviews, renal involvement contributing to fluoride retention itself (kidneys clear fluoride; impaired renal function reduces excretion and worsens skeletal accumulation).
• Body systems: skeletal, nervous (compressive), and to a lesser extent muscular systems; endocrine system implicated via PTH/vitamin D axis perturbation.
• Tissue/cell level: bone (cortical and trabecular), articular/enthesis connective tissue and ligaments (interosseous membrane, posterior longitudinal ligament, ligamentum flavum — sites of pathological ossification), cartilage (chondrocyte apoptosis/matrix degradation), and spinal neural tissue (secondary compression injury).
• Cell populations targeted: osteoblasts (hyperactivated), osteocytes (apoptosis/mitophagy), osteoclasts (RANK-pathway-driven differentiation), chondrocytes (apoptosis, autophagy).
• Subcellular level: mitochondria (ROS generation, mitophagy in osteocytes), endoplasmic reticulum (UPR/ER stress via PERK-ATF4), nucleus (β-catenin nuclear translocation, epigenetic/DNA methylation changes).
• Localization (UBERON): vertebral column (UBERON:0002298 vertebral column), pelvis, forearm bones, sacroiliac joint, spinal cord (UBERON:0002240), long bones. Ossification is generalized/bilateral rather than lateralized.

Suggested UBERON terms: UBERON:0001474 (bone element), UBERON:0002240 (spinal cord), UBERON:0002298 (vertebral column), UBERON:0002228 (rib), UBERON:0002417 (posterior longitudinal ligament — if available), UBERON:0004123 (femur), UBERON:0001103 (diaphragm — n/a, remove if not applicable).

8. Temporal Development

• Onset: Typically adult-onset (years to decades of cumulative exposure) in endemic waterborne fluorosis; pediatric-onset described specifically in indoor coal-smoke fluorosis in China (PMC2778178); rare subacute-onset (months) cases from inhalant abuse or high-dose methoxyflurane exposure.
• Onset pattern: Insidious/chronic in the overwhelming majority of cases; subacute in iatrogenic/abuse-related cases.
• Progression / staging: Chinese national standard WS/T192-2021 defines three grades — Grade I (symptomatic, no radiographic/physical signs), Grade II (typical clinical and radiographic manifestations, retains partial work capacity), Grade III (loss of work capacity, "crippling" disease) (search synthesis). Radiographically, changes are described along a spectrum: early sand-like/granular trabecular thickening → osteosclerosis, osteopenia in some regions, diaphyseal widening, intermittent growth-arrest lines, and soft-tissue/ligamentous ossification, with the most pronounced structural changes typically appearing in middle age (40–60 years) (search synthesis of radiographic reviews).
• Progression rate: Slow and dose/duration-dependent; neurologic complications generally require >10 years of exposure at >4 ppm fluoride.
• Course pattern: Chronic and generally progressive with continued exposure; not classically relapsing-remitting.
• Reversibility: Cessation of exposure can lead to gradual improvement/reversal of biochemical and even some radiographic abnormalities, but recovery is extremely slow — potentially requiring years to decades — consistent with fluoride's estimated ~7-year half-life in bone; a well-documented American case showed "considerable correction" only after nearly a decade of source removal (toothpaste) (PMID:17014382). No large systematic reversibility dataset exists; evidence is case-based.
• Critical periods: Exposure before ~age 8 additionally risks concurrent dental fluorosis (enamel formation window); no other defined critical developmental window is described for the skeletal phenotype beyond cumulative dose-duration.

9. Inheritance and Population

• Inheritance pattern: Not applicable in the Mendelian sense — skeletal fluorosis is an acquired toxic/environmental disease. "Inheritance" language does not apply; susceptibility is polygenic/multifactorial (see COL1A1/ESR1 modifiers, Section 4), analogous to a gene-by-environment susceptibility trait rather than a classic inherited disorder. Penetrance, expressivity, anticipation, germline mosaicism, founder effects, and carrier frequency are not meaningful concepts here except insofar as modifier-allele frequency (e.g., COL1A1 rs1800012, ESR1 rs9340799) differs by ethnicity, as documented in the Tibetan/Kazakh/Mongolian/Russian comparison cohort (PMID:39824337).

• Epidemiology:

• Global burden: UNICEF estimates fluorosis (dental + skeletal combined) is endemic in at least 25 countries, with approximately 200 million people at health risk from elevated groundwater fluoride; some reviews cite over 100 affected countries (search synthesis, PMC13275634). India and China are described as the two largest-affected countries.
• India (regional surveys): Kankar district, Chhattisgarh — dental fluorosis prevalence 24.8%, skeletal fluorosis 6.0%. Vidharbha region, Maharashtra — skeletal fluorosis prevalence 56.9% in males, 43.1% in females among the surveyed endemic population (PMC2940190).
• China: Fluorosis affects 28 provincial-level administrative regions and over 70,000 villages, via three main pathways — coal-burning, drinking-water contamination, and brick-tea consumption (PMC13128821).
• Geographic distribution: Endemic belts include the Indian subcontinent, northern/southwestern China, the East African Rift Valley (Ethiopia, Kenya, Tanzania, Uganda, Eritrea, Djibouti), parts of the Middle East (Jordan, Lebanon, Israel), Sri Lanka, and Türkiye (search synthesis, ResearchGate distribution figure, PMC13275634).
• Sex ratio: Male predominance reported in at least one Indian endemic-village study (see above); mechanistic basis (behavioral/occupational exposure vs. biological susceptibility) not fully resolved in the sources reviewed.
• Age distribution: Peak radiographic severity in the 40–60 year age range, reflecting cumulative dose; pediatric cases occur specifically in the coal-smoke exposure pathway.

10. Diagnostics

• Diagnostic criteria (composite): (1) residence history in a fluorosis-endemic area or a documented alternative fluoride source; (2) characteristic clinical symptoms — persistent resting pain in ≥3 regions (major limb joints, neck, lower back) unaffected by season, and/or restricted joint mobility or secondary neurologic impairment; (3) characteristic radiographic findings; (4) elevated urinary (and/or bone) fluoride. Diagnosis rests on this combination with exclusion of radiographic mimics (search synthesis).
• Imaging (primary diagnostic modality):
• Plain radiography remains the mainstay: hallmark findings are generalized osteosclerosis, diffuse periostitis, entheso-/ligamentous ossification (interosseous membranes, posterior longitudinal ligament, ligamentum flavum), and sacroiliac changes without erosions — distinguishing SF from inflammatory spondyloarthropathies (search synthesis; AJR classic series of 127 patients).
• Early disease: sand-like/granular trabecular thickening at trabecular junctions.
• A novel structured scoring system, FI-RADS (Fluorosis Imaging-Reporting and Data System), has been proposed (2026) combining imaging with clinical/biochemical analysis for standardized severity scoring (PMC13178315; PMID:42147921).
• Advanced cases can radiographically mimic multiple myeloma on spinal MRI (PMC5117116).
• Laboratory tests / biomarkers:
• Urinary fluoride — the principal chemical biomarker of recent/ongoing exposure (elevated to ~15–20 ppm vs. 2–6 ppm normal, cross-species comparative data).
• Bone-ash fluoride content (biopsy) — gold-standard definitive test but invasive, rarely performed.
• Serum fluoride is generally not diagnostically useful because it reflects only very recent intake.
• Elevated PTH, elevated alkaline phosphatase, and disturbed calcium/phosphorus panels are supportive but nonspecific.
• Genetic testing: Not applicable as a diagnostic modality (no causal gene); COL1A1/ESR1 genotyping is a research tool for population-susceptibility studies, not clinical diagnosis.
• Differential diagnosis: Ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis (DISH) are the principal radiographic mimics. Distinguishing features: AS shows complete sacroiliac joint fusion and "smooth-type" anterior spinal bony bridging; DISH shows anterior/posterior bony bridging around the SI joint without fusion and "candle-wax-type" bridging. The combination of diffuse osteosclerosis with periosteal reaction plus ligament/tendon mineralization should specifically prompt consideration of skeletal fluorosis and a focused exposure history (search synthesis, PMC9892029 comparative radiology study).
• Other mimics to exclude: renal osteodystrophy, osteopetrosis, Paget disease of bone, myelofibrosis, and (as noted) multiple myeloma on imaging alone.

11. Outcome / Prognosis

• Mortality: No direct disease-specific mortality/survival statistics (e.g., 5-year survival) were identified — skeletal fluorosis is not typically fatal per se, but severe neurologic complications (quadriparesis) carry major morbidity and disability risk.
• Morbidity/disability: Advanced (Grade III) disease causes loss of work capacity; the case-series literature explicitly frames the disease as a "continuing crippling challenge," with impaired health-related quality of life (search synthesis, ScienceDirect S2214624522000089).
• Reversibility/recovery: As detailed in Section 8, cessation of the fluoride source can allow gradual clinical, biochemical, and radiographic improvement, but recovery is slow (years, potentially matching bone fluoride's ~7-year half-life), and a well-documented case required nearly a decade for substantial correction after removing a toothpaste source (PMID:17014382). There are no systematic reversibility data across cohorts — this is characterized as an evidence gap in the literature itself.
• Complications: Compressive myelopathy/radiculopathy (5–10% of cases, see Section 3/6), joint ankylosis, secondary muscle changes, and (in the pediatric coal-smoke pathway) growth/limb deformities (e.g., genu varum/valgum).
• Prognostic factors: Total cumulative fluoride dose and duration of exposure are described as "the single most important factor" determining clinical course (search synthesis, PubMed abstract on endemic skeletal fluorosis); early removal of the fluoride source is the dominant modifiable prognostic factor, since no pharmacologic treatment reverses established disease.

12. Treatment

There is no disease-modifying pharmacologic treatment for established skeletal fluorosis. Management is source removal plus symptomatic/supportive care.

• Primary intervention: Identification and elimination of the fluoride source (switching water supply, discontinuing brick tea, ceasing occupational exposure, stopping inhalant abuse or methoxyflurane), which is the only intervention shown to allow gradual improvement (Section 8/11).
• Pharmacotherapy (symptomatic):
• NSAIDs for pain and inflammation control (NCIT:C15986 Pharmacotherapy; specific agent class NCIT:C275/analgesic).
• Calcium and vitamin D supplementation — mixed evidence in humans (largely minimal efficacy reported in clinical literature), but effective in mouse models at alleviating dental/skeletal fluorosis, reducing bone fluoride deposition, and normalizing elemental (Ca/P) homeostasis (PMID:33057951; evidence_source: MODEL_ORGANISM for the murine result vs. HUMAN_CLINICAL for the largely negative human experience).
• Surgical/interventional:
• Decompressive laminectomy for relief of neurologic deficits from spinal cord/nerve root compression (NCIT:C15329 Surgical Procedure) — but note a documented case of recurrent fluorotic cervical compressive myelopathy 20 years after laminectomy, illustrating that surgery addresses mechanical compression without halting the underlying ossifying process if exposure continues (Surgical Neurology International case report).
• Osteoplasty for ankylosis of appendicular joints.
• Supportive/rehabilitative care: Physical therapy (NCIT:C15302) and general symptomatic musculoskeletal pain management, particularly important during a prolonged "withdrawal phase" after source removal that may last many weeks.
• Experimental/research-stage: No specific ongoing registered clinical trials targeting skeletal fluorosis treatment were identified in this search (ClinicalTrials.gov search returned no disease-specific NCT records); a 2026 "China Fluorosis Cohort (CFC)" randomized trial explores drug–lifestyle interventions but targets cardiovascular-metabolic outcomes in fluorosis patients rather than the skeletal phenotype itself (Frontiers in Pharmacology, 2026).
• Treatment outcomes: Human calcium/vitamin D trials show minimal efficacy in established disease; surgical decompression provides mechanical relief but does not reverse the underlying osteosclerotic process.

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy), NCIT:C15329 (Surgical Procedure), NCIT:C15302 (Physical Therapy), NCIT:C15747 (Supportive Care). Suggested CHEBI terms for the causal/therapeutic agents: CHEBI:17051 (fluoride ion, the causal agent), CHEBI:28741 (sodium fluoride), CHEBI:22984 (calcium(2+); for calcium supplementation), CHEBI:27300 (vitamin D).

13. Prevention

• Primary prevention (population level):
• Defluoridation of drinking water to bring fluoride concentration to WHO's guideline ≤1.5 mg/L — via technologies such as octacalcium-phosphate/fluorapatite transformation systems and household-scale defluoridators (demonstrated in Tanzania to reduce 21 mg/L source water to below the WHO limit within 2 hours) (PMC7687156, PMC6706606).
• Alternative/safe water source provision in endemic villages.
• Reduction/substitution of brick tea consumption in high-risk pastoralist populations, with documented reversal of biochemical/clinical parameters after tea reduction or cessation (ScienceDirect S237606052030465X).
• Improved ventilation and alternative cooking fuel to reduce indoor coal-smoke exposure, plus altered crop-drying practices (not drying food over open coal fires) in the southwestern China pediatric-fluorosis context.
• Occupational hygiene controls (ventilation, personal protective equipment, exposure monitoring) in fluoride-emitting industries.
• Secondary prevention: Population screening in endemic areas via urinary fluoride testing and radiographic surveillance to detect early (Grade I) disease before irreversible skeletal changes accrue; public health surveys of the type reviewed above (e.g., Chhattisgarh, Vidharbha, Andhra Pradesh school-children studies) serve this function.
• Tertiary prevention: Early source removal upon diagnosis to halt disease progression and permit the slow reversal process described in Sections 8/11; symptomatic management to prevent secondary complications (e.g., early recognition of neurologic signs to prompt timely decompressive surgery before irreversible cord injury).
• Counseling: Public health education in endemic communities regarding water source safety and tea consumption patterns; occupational counseling in at-risk industries.
• Regulatory/public health standards: WHO drinking-water guideline value of 1.5 mg/L fluoride, adopted as national standard in most countries (some countries with particular challenges set different limits) (search synthesis).

14. Other Species / Natural Disease

• Taxonomy of affected species: Skeletal fluorosis occurs naturally in numerous species exposed to high-fluoride water, forage, or industrial contamination — most notably cattle (Bos taurus, NCBITaxon:9913), but also documented in horses, sheep, and other livestock, as well as wildlife in fluoride-contaminated environments (Merck Veterinary Manual; veterinaryworld.org review).
• Natural disease in veterinary species (cattle): Skeletal fluorosis in cattle presents with hoof deformity, mandibular lesions, bone/joint enlargement, exostoses, ligament calcification, stiffness, and lameness, at drinking-water fluoride concentrations of ≥2.8 mg/L (search synthesis, veterinaryworld.org, cpdsolutions.co.za review). Diagnostic thresholds: bone fluoride concentration of 1605–2794 mg/kg (age-dependent) for chronic fluorosis; urinary fluoride <5 ppm normal, 20–30 ppm borderline toxicity, >35 ppm with systemic signs.
• Causes in livestock: deep-well/artesian bore water, industrial (e.g., aluminum smelter, phosphate fertilizer plant) contamination of pasture/forage, and high soil fluoride affecting fodder crops.
• Veterinary relevance: Fluorosis is an economically significant livestock disease in endemic regions (India, parts of Africa) causing reduced productivity, lameness, and premature culling; it is diagnosed via the same combination of history, clinical signs, radiography, and bone/urine fluoride analysis used in humans (Livesey, In Practice, 2011, doi:10.1136/inp.d6078).
• Comparative pathology: The core pathophysiology — fluoride substitution into hydroxyapatite, osteosclerosis, exostosis formation, ligament calcification — is conserved across mammalian species, supporting cattle and mice as translationally relevant natural/experimental models. Dental fluorosis is separately documented as co-occurring in livestock sharing contaminated water/pasture with human populations (e.g., Gihaya Island, Lake Kivu, Rwanda cohort, PMC8686390).
• Zoonotic potential: Not applicable — this is a shared environmental toxic exposure, not a transmissible infectious disease.
• OMIA: No specific OMIA (Online Mendelian Inheritance in Animals) entry was identified for fluorosis in this search, consistent with its non-Mendelian, acquired-toxicological nature; direct OMIA database consultation would be needed to confirm absence of an entry.

15. Model Organisms

• Mouse (Mus musculus, NCBITaxon:10090) — the dominant experimental model:
• Genetic/strain models: Comparative dosing (0, 25, 50, 100 ppm F in food/water) across three inbred strains with differential enamel-fluorosis susceptibility — A/J (susceptible), 129P3/J (resistant), SWR/J (intermediate) — shows strain-dependent, dose-concordant increases in femoral and vertebral fluoride concentration, establishing a genetic-background model for susceptibility (PMID:16920415).
• Proteomic follow-up: 8-week exposure to 0/10/50 ppm F in A/J vs. 129P3/J mice shows bone proteomic changes (36 differentially abundant proteins) even at low dose in the susceptible strain (PMC4263599) — useful for identifying candidate mechanistic biomarkers.
• Intervention model: Calcium/vitamin D supplementation in a fluorosis mouse model effectively alleviates dental and skeletal fluorosis and retains elemental homeostasis (PMID:33057951) — the strongest available "rescue" evidence for this intervention, notably stronger than the human clinical experience, an instructive human/model discrepancy for a HUMAN_MODEL_MISMATCH-type discussion.
• Method development: A murine model using hexamethyldisiloxane-facilitated diffusion with ion-selective electrode measurement enables age- and dose-dependent fluoride quantification across serum, bone, and teeth (PMID:42667223), supporting future dose-response and toxicokinetic studies.
• Developmental-age model: Classic studies (PMID:1058056, PMID:1060516, PMID:1067906) examined age-of-exposure effects on incisor/bone fluoride incorporation and the influence of dietary salt intake on fluoride uptake in mice.
• Rat (Rattus norvegicus, NCBITaxon:10116): Wistar rats treated with sodium fluoride used for iTRAQ-based serum proteomic biomarker discovery relevant to fluorosis mechanism/candidate biomarkers (PMC5085677); primary rat osteoblast cultures used to demonstrate fluoride-induced Wnt/β-catenin activation via Akt/GSK-3β (PMID:24300170).
• Cattle (Bos taurus) as a natural disease model (Section 14) — valuable for translational relevance given spontaneous, environmentally acquired disease closely paralleling the human condition, though whole-organism veterinary studies are largely observational rather than mechanistic/genetic.
• Model limitations: Rodent models require relatively high fluoride doses (tens to over 100 ppm) delivered over weeks to reproduce skeletal changes analogous to those developing over years to decades of low-level (~1.5–10 ppm water; higher via tea/coal) human exposure — a scale/dose-rate divergence to note explicitly when using rodent data to support human mechanism claims. No organoid, iPSC, zebrafish, or single-cell/spatial-transcriptomic fluorosis-specific model was identified in this search, representing an apparent gap in the current published model landscape relative to other skeletal disorders.
• Resources: MGI (Mouse Genome Informatics) for strain background data; no dedicated fluorosis-specific model registry was identified.

Summary of Suggested Ontology Term Bindings

Notable Evidence Gaps (flagged for curation)

1. Reversibility/prognosis is documented almost entirely through single case reports (e.g., PMID:17014382), not cohort data — the literature itself states "there are no data regarding its reversibility" at a systematic level.
2. No specific registered clinical trials target skeletal-fluorosis treatment directly (ClinicalTrials.gov search returned none disease-specific); the one identified 2026 trial (China Fluorosis Cohort) targets cardiovascular-metabolic, not skeletal, endpoints.
3. Human calcium/vitamin D efficacy is discordant with the mouse model result (minimal human efficacy vs. clear murine rescue, PMID:33057951) — a candidate HUMAN_MODEL_MISMATCH discussion point.
4. No QoL instrument (EQ-5D/SF-36) score data specific to skeletal fluorosis were located; impact is described narratively only.
5. OMIA entry status for veterinary fluorosis was not confirmed/denied definitively and would need direct OMIA database consultation.

Sources: - Progress of Signaling Pathways, Stress Pathways and Epigenetics in the Pathogenesis of Skeletal Fluorosis (PMC8584317 / PMID:34769866) - Environmental fluoride exposure and bone metabolism: Molecular pathways and health implications (PMID:42336527) - The continuing crippling challenge of skeletal fluorosis – Case series and review of literature - Skeletal fluorosis in humans: a review of recent progress (PMID:3295994) - MONDO:0400003 — Ontology Lookup Service - ICD-10-CM M85.1 series — icd10data.com - Effect of fluoride on osteocyte-driven osteoclastic differentiation (PMID:32156525) - Different Effects of Fluoride Exposure on the Three Major Bone Cell Types - Apoptosis and Inflammation Involved with Fluoride-Induced Bone Injuries (PMC11313706) - Fluoride Exposure and Skeletal Fluorosis: a Systematic Review and Dose-response Meta-analysis - Child Skeletal Fluorosis from Indoor Burning of Coal in Southwestern China (PMC2778178) - Predicting skeletal fluorosis severity using machine learning across diverse fluoride-exposed populations in China (PMC13128821) - Assessment of Skeletal and Non-skeletal Fluorosis in Endemic Fluoridated Areas of Vidharbha Region, India (PMC2940190) - FI-RADS: an imaging-based scoring system for skeletal fluorosis (PMC13178315 / PMID:42147921) - Endemic fluorosis of the skeleton: radiographic features in 127 patients — AJR - Neurological complications of endemic skeletal fluorosis, with special emphasis on radiculo-myelopathy (PMID:2172892) - Neurology of endemic skeletal fluorosis — Neurology India - Multiple Myeloma-Like Spinal MRI Findings in Skeletal Fluorosis (PMC5117116) - Fluorotic cervical compressive myelopathy, 20 years after laminectomy - Fluoride promotes osteoblastic differentiation through canonical Wnt/β-catenin signaling pathway (PMID:24300170) - Association between ESR1 and COL1A1 gene polymorphisms and skeletal fluorosis in Tibetan, Kazakh, Mongolian and Russian populations, China (PMID:39824337) - The genetic influence in fluorosis - The COL1A2 gene polymorphism among a Tunisian Population and Dental Fluorosis (PMC10958825) - Fluorosis in Cattle — veterinaryworld.org - Diagnosis and investigation of fluorosis in livestock and horses — In Practice - Fluoride Poisoning in Animals — Merck Veterinary Manual - Chronic Fluoride Exposure from Brick Tea Consumption Disrupts Bone Remodeling (PMID:42060046) - Skeletal Fluorosis Related to Habitual Tea Consumption: Long-Term Follow-Up - Prevalence of Brick Tea-Type Fluorosis in the Tibet Autonomous Region (PMC4728115) - Skeletal fluorosis from the point of view of an occupational exposure in former Czechoslovakia (PMC2993488) - Skeletal Fluorosis: An Unusual Manifestation of Computer Cleaner Inhalant Abuse (PMC7336600) - Skeletal fluorosis secondary to methoxyflurane use for chronic pain — JBMR Plus - Recovery From Skeletal Fluorosis (an Enigmatic, American Case) — JBMR (PMID:17014382) - Calcium and Vitamin D Supplementation Effectively Alleviates Dental and Skeletal Fluorosis in Mice (PMID:33057951) - Treatment and Prevention of Skeletal Fluorosis - Global groundwater contamination by geogenic fluoride (PMC13275634) - Application of Octacalcium Phosphate defluoridator prototype in East African Rift Valley communities (PMC7687156) - Defluoridation of water through transformation of octacalcium phosphate into fluorapatite (PMC6706606) - The genetic influence on bone susceptibility to fluoride (PMID:16920415) - Bone Response to Fluoride Exposure Is Influenced by Genetics (PMC4263599) - Quantification of Fluoride in Serum, Bone, and Teeth in a Murine Model (PMID:42667223) - iTRAQ-Based Proteomics Analysis of Serum Proteins in Wistar Rats Treated with Sodium Fluoride (PMC5085677) - Studies on skeletal muscle biopsies in endemic skeletal fluorosis (PMID:10878791) - Comparison of radiological characteristics between DISH and ankylosing spondylitis (PMC9892029) - Fluoride Exposure Provokes Mitochondria-Mediated Apoptosis and Increases Mitophagy in Osteocytes - Sodium fluoride accelerates apoptosis, oxidative stress and matrix degradation of condylar chondrocytes (PMID:39959228) - Pentose phosphate pathway regulates oxidative damage and apoptosis of chondrocytes induced by fluoride (PMID:41601087) - fluoride (CHEBI:17051) - Dental fluorosis among people and livestock, Gihaya Island, Lake Kivu, Rwanda (PMC8686390)

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:34769866 (1 mention) - How Did School Meal Access Change during the COVID-19 Pandemic? A Two-Step Floating Catchment Area Analysis of a Large Metropolitan Area.
• shared terms: change

Weighed against this report's own most characteristic terms: skeletal, fluoride, fluorosis, exposure, bone, disease, dental, endemic, synthesis, radiographic, clinical, year, chronic, change, tea, calcium, china, joint, water, via.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0400003 (4 mentions) - the report calls it "Skeletal fluorosis", "Ontology Lookup Service"; MONDO calls it skeletal fluorosis
• HP:0100774 (2 mentions) - the report calls it "Osteosclerosis"; HP calls it Hyperostosis
• HP:0009758 (1 mention) - the report calls it "Enamel hypoplasia"; HP calls it Pyramidal skinfold extending from the base to the top of the nails
• UBERON:0002298 (3 mentions) - the report calls it "vertebral column"; UBERON calls it brainstem
• UBERON:0002417 (1 mention) - the report calls it "posterior longitudinal ligament — if available"; UBERON calls it abdominal segment of trunk
• UBERON:0004123 (1 mention) - the report calls it "femur"; UBERON calls it myocardial layer

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002510 (2 mentions) - the report calls it "Spastic tetraparesis"; HP calls it Spastic tetraplegia
• GO:0007224 (1 mention) - the report calls it "smoothened signaling pathway, Hedgehog"; GO calls it smoothened signaling pathway
• GO:0043491 (1 mention) - the report calls it "protein kinase B signaling, PI3K/Akt"; GO calls it phosphatidylinositol 3-kinase/protein kinase B signal transduction, and lists "protein kinase B signaling" among its other names
• UBERON:0001103 (1 mention) - the report calls it "diaphragm — n/a, remove if not applicable"; UBERON calls it diaphragm, and lists "diaphragm of thorax" among its other names
• NCIT:C15302 (3 mentions) - the report calls it "Supportive/rehabilitative care: Physical therapy", "Physical Therapy"; NCIT calls it Physical Therapy**
• CHEBI:17051 (5 mentions) - the report calls it "fluoride ion, the causal agent", "fluoride"; CHEBI calls it fluoride, and lists "FLUORIDE ION" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0400003 - called "Skeletal fluorosis", "Ontology Lookup Service"
• MONDO:0006722 - called "dental fluorosis", "Dental fluorosis"
• NCIT:C15302 - called "Supportive/rehabilitative care:** Physical therapy", "Physical Therapy"
• CHEBI:17051 - called "fluoride ion, the causal agent", "fluoride"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ICD10CM.